Home › Compare › QPTFF vs JNJ

QPTFF vs JNJ: Dividend Comparison 2026

QPTFF yields 6578.95% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QPTFF wins by $903160944306728.13M in total portfolio value
10 years
QPTFF
QPTFF
● Live price
6578.95%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$903160944306728.13M
Annual income
$876,939,829,008,324,100,000.00
Full QPTFF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — QPTFF vs JNJ

📍 QPTFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQPTFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QPTFF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
QPTFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QPTFF
Annual income on $10K today (after 15% tax)
$559,210.53/yr
After 10yr DRIP, annual income (after tax)
$745,398,854,657,075,400,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, QPTFF beats the other by $745,398,854,657,075,400,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QPTFF + JNJ for your $10,000?

QPTFF: 50%JNJ: 50%
100% JNJ50/50100% QPTFF
Portfolio after 10yr
$451580472153364.06M
Annual income
$438,469,914,504,162,050,000.00/yr
Blended yield
97.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

QPTFF
No analyst data
Altman Z
2.1
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QPTFF buys
0
JNJ buys
0
No recent congressional trades found for QPTFF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQPTFFJNJ
Forward yield6578.95% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$903160944306728.13M ✓$20.0K
Annual income after 10y$876,939,829,008,324,100,000.00 ✓$827.78
Total dividends collected$901400901751488.63M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QPTFF vs JNJ ($10,000, DRIP)

YearQPTFF PortfolioQPTFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$668,595$657,894.74$10,676$355.77+$657.9K → QPTFF
2$41,824,271$41,108,874.62$11,407$389.39+$41.81M → QPTFF
3$2,448,103,158$2,403,351,188.44$12,198$426.53+$2448.09M → QPTFF
4$134,091,931,604$131,472,461,224.39$13,056$467.62+$134091.92M → QPTFF
5$6,873,616,037,527$6,730,137,670,710.89$13,987$513.12+$6873616.02M → QPTFF
6$329,775,376,912,396$322,420,607,752,241.75$14,998$563.56+$329775376.90M → QPTFF
7$14,809,652,943,541,940$14,456,793,290,245,678.00$16,098$619.52+$14809652943.53M → QPTFF
8$622,603,404,175,321,200$606,757,075,525,731,300.00$17,295$681.69+$622603404175.30M → QPTFF
9$24,505,715,232,153,338,000$23,839,529,589,685,744,000.00$18,599$750.82+$24505715232153.32M → QPTFF
10$903,160,944,306,728,100,000$876,939,829,008,324,100,000.00$20,022$827.78+$903160944306728.13M → QPTFF

QPTFF vs JNJ: Complete Analysis 2026

QPTFF — Stock

Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Full QPTFF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this QPTFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QPTFF vs SCHDQPTFF vs JEPIQPTFF vs OQPTFF vs KOQPTFF vs MAINQPTFF vs ABBVQPTFF vs MRKQPTFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.